Skip to main content

Table 2 Comparison of PET and CT responses at time of discontinuation

From: Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma

  CMR
(n = 34)
Non-CMR
(n = 4)
RECIST v1.1 response*
 CR (n = 13) 13 (38.2%) 0 (0%)
 PR (n = 21) 18 (52.9%) 3 (75.0%)
 SD (n = 4) 3 (8.8%) 1 (25.0%)
  1. Abbreviations: CR complete response, CMR, complete morphological response, PR partial response, SD stable disease